Mirtazapine Biogaran

Mirtazapine, the active ingredient in Mirtazapine Biogaran, is a tetracyclic antidepressant presented as a tablet for oral use. It treats major depressive disorder in adult patients and is prescribed when improvement of mood, sleep and appetite is needed.

GNH USA supplies Mirtazapine Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on central neurotransmitter systems involved in mood regulation and is indicated for several depressive conditions. - Major depressive disorder: reduces depressive symptoms and improves overall mood. - Depressive episodes in bipolar disorder (adjunct): helps alleviate depressive phase when used with mood stabilisers. - Depression with insomnia or loss of appetite: improves sleep quality and stimulates appetite, supporting nutritional status.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness. - Increased appetite leading to weight gain. - Dry mouth. - Constipation. - Dizziness.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Seizures, particularly in predisposed individuals. - Hepatic dysfunction or jaundice. - Severe hypotension or orthostatic collapse.

Before initiating therapy, clinicians should evaluate specific risk factors and monitor patients appropriately. - Pregnancy: avoid unless benefits outweigh potential risks to the fetus. - Elderly patients: start at low dose and monitor for excessive sedation. - Concomitant CNS depressants: increased risk of profound drowsiness. - History of bipolar disorder: monitor for emergence of manic symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other central nervous system depressants (e.g., benzodiazepines, opioids): may cause profound sedation. - Serotonergic agents (e.g., SSRIs, SNRIs, triptans): increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Alcohol: additive CNS depression and impaired coordination. - Antihistamines: may enhance sedative effects.